BRIEF published on 11/04/2024 at 20:10, 1 year 1 month ago Evolution of the number of shares and voting rights of Poxel in 2024 Share Capital Voting Rights Actions AMF Biopharmaceutical
BRIEF published on 10/11/2024 at 07:35, 1 year 1 month ago Poxel Releases 2023 Universal Registration Document Corporate Governance Annual Financial Report CSR Report Poxel 2023 Registration Document
PRESS RELEASE published on 10/11/2024 at 07:30, 1 year 1 month ago Annual financial and audit reports / Terms of availability of the annual financial report Poxel announces availability of the 2023 Universal Registration Document including financial and governance reports, now filed with the AMF AMF Biopharmaceutical Company Financial Report Universal Registration Document Poxel
BRIEF published on 10/03/2024 at 18:35, 1 year 2 months ago Poxel announces its financial and strategic results for 2023 Financial Results Biopharmaceutical TWYMEEG® Poxel OrbiMed
BRIEF published on 09/30/2024 at 07:35, 1 year 2 months ago Poxel Secures $50M Non-Dilutive Financing from OrbiMed Non-dilutive Financing TWYMEEG® Poxel Royalty Monetization OrbiMed
PRESS RELEASE published on 09/30/2024 at 07:30, 1 year 2 months ago Inside Information / Other news releases Poxel monetizes TWYMEEG® royalties in a USD 50 million deal with OrbiMed. Proceeds to reduce debt and support rare disease activities. Webinars scheduled for investor updates Webinars Royalties TWYMEEG® Poxel OrbiMed
BRIEF published on 09/09/2024 at 07:35, 1 year 2 months ago POXEL announces a significant increase in its sales in the second quarter of 2024 Sales Treasury Partnerships TWYMEEG® Poxel
BRIEF published on 08/16/2024 at 08:16, 1 year 3 months ago Poxel: Evolution of the Share Capital and the Number of Voting Rights Share Capital Voting Rights Actions AMF Poxel
BRIEF published on 08/07/2024 at 08:05, 1 year 3 months ago Sumitomo Pharma and Poxel Unveil Study Results of TWYMEEG® for Type 2 Diabetes TWYMEEG® Poxel Sumitomo Pharma Type 2 Diabetes Renal Failure
PRESS RELEASE published on 08/07/2024 at 08:00, 1 year 3 months ago Inside Information / Other news releases Sumitomo Pharma and Poxel announce topline results from post-marketing clinical study on TWYMEEG(R) for Type 2 Diabetes treatment in Japan. Safety, tolerability confirmed in renal impairment patients Japan Poxel Sumitomo Pharma Type 2 Diabetes TWYMEEG
Published on 12/05/2025 at 02:35, 5 hours 28 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 3 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 58 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 3 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 1 hour 3 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 33 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 38 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 48 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 14 hours 3 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 18 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 19 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago Declaration of voting rights at the end of November 2025
